204 related articles for article (PubMed ID: 30544937)
1. Structural Features of Heparan Sulfate from Multiple Osteochondromas and Chondrosarcomas.
Veraldi N; Parra A; Urso E; Cosentino C; Locatelli M; Corsini S; Pedrini E; Naggi A; Bisio A; Sangiorgi L
Molecules; 2018 Dec; 23(12):. PubMed ID: 30544937
[TBL] [Abstract][Full Text] [Related]
2. Decreased EXT expression and intracellular accumulation of heparan sulphate proteoglycan in osteochondromas and peripheral chondrosarcomas.
Hameetman L; David G; Yavas A; White SJ; Taminiau AH; Cleton-Jansen AM; Hogendoorn PC; Bovée JV
J Pathol; 2007 Mar; 211(4):399-409. PubMed ID: 17226760
[TBL] [Abstract][Full Text] [Related]
3. Secondary peripheral chondrosarcoma evolving from osteochondroma as a result of outgrowth of cells with functional EXT.
de Andrea CE; Reijnders CM; Kroon HM; de Jong D; Hogendoorn PC; Szuhai K; Bovée JV
Oncogene; 2012 Mar; 31(9):1095-104. PubMed ID: 21804604
[TBL] [Abstract][Full Text] [Related]
4. Up-regulation of PTHrP and Bcl-2 expression characterizes the progression of osteochondroma towards peripheral chondrosarcoma and is a late event in central chondrosarcoma.
Bovée JV; van den Broek LJ; Cleton-Jansen AM; Hogendoorn PC
Lab Invest; 2000 Dec; 80(12):1925-34. PubMed ID: 11140704
[TBL] [Abstract][Full Text] [Related]
5. The pathogenic roles of heparan sulfate deficiency in hereditary multiple exostoses.
Pacifici M
Matrix Biol; 2018 Oct; 71-72():28-39. PubMed ID: 29277722
[TBL] [Abstract][Full Text] [Related]
6. EXT-mutation analysis and loss of heterozygosity in sporadic and hereditary osteochondromas and secondary chondrosarcomas.
Bovée JV; Cleton-Jansen AM; Wuyts W; Caethoven G; Taminiau AH; Bakker E; Van Hul W; Cornelisse CJ; Hogendoorn PC
Am J Hum Genet; 1999 Sep; 65(3):689-98. PubMed ID: 10441575
[TBL] [Abstract][Full Text] [Related]
7. No haploinsufficiency but loss of heterozygosity for EXT in multiple osteochondromas.
Reijnders CM; Waaijer CJ; Hamilton A; Buddingh EP; Dijkstra SP; Ham J; Bakker E; Szuhai K; Karperien M; Hogendoorn PC; Stringer SE; Bovée JV
Am J Pathol; 2010 Oct; 177(4):1946-57. PubMed ID: 20813973
[TBL] [Abstract][Full Text] [Related]
8. Peripheral chondrosarcoma progression is associated with increased type X collagen and vascularisation.
de Andrea CE; Wiweger MI; Bovée JV; Romeo S; Hogendoorn PC
Virchows Arch; 2012 Jan; 460(1):95-102. PubMed ID: 22116208
[TBL] [Abstract][Full Text] [Related]
9. Signaling systems affecting the severity of multiple osteochondromas.
Piombo V; Jochmann K; Hoffmann D; Wuelling M; Vortkamp A
Bone; 2018 Jun; 111():71-81. PubMed ID: 29545125
[TBL] [Abstract][Full Text] [Related]
10. Somatic loss of an EXT2 gene mutation during malignant progression in a patient with hereditary multiple osteochondromas.
Musso N; Caronia FP; Castorina S; Lo Monte AI; Barresi V; Condorelli DF
Cancer Genet; 2015 Mar; 208(3):62-7. PubMed ID: 25744876
[TBL] [Abstract][Full Text] [Related]
11. Differentiation-induced loss of heparan sulfate in human exostosis derived chondrocytes.
Hecht JT; Hayes E; Haynes R; Cole WG; Long RJ; Farach-Carson MC; Carson DD
Differentiation; 2005 Jun; 73(5):212-21. PubMed ID: 16026543
[TBL] [Abstract][Full Text] [Related]
12. Aberrant heparan sulfate proteoglycan localization, despite normal exostosin, in central chondrosarcoma.
Schrage YM; Hameetman L; Szuhai K; Cleton-Jansen AM; Taminiau AH; Hogendoorn PC; Bovée JV
Am J Pathol; 2009 Mar; 174(3):979-88. PubMed ID: 19179614
[TBL] [Abstract][Full Text] [Related]
13. Osteochondroma formation is independent of heparanase expression as revealed in a mouse model of hereditary multiple exostoses.
Mundy C; Chung J; Koyama E; Bunting S; Mahimkar R; Pacifici M
J Orthop Res; 2022 Oct; 40(10):2391-2401. PubMed ID: 34996123
[TBL] [Abstract][Full Text] [Related]
14. Targeted Next-Generation Sequencing Newly Identifies Mutations in Exostosin-1 and Exostosin-2 Genes of Patients with Multiple Osteochondromas.
Guo X; Lin M; Shi T; Yan W; Chen W
Tohoku J Exp Med; 2017 Jul; 242(3):173-181. PubMed ID: 28690282
[TBL] [Abstract][Full Text] [Related]
15. Heparan sulfate deficiency leads to hypertrophic chondrocytes by increasing bone morphogenetic protein signaling.
Kawashima K; Ogawa H; Komura S; Ishihara T; Yamaguchi Y; Akiyama H; Matsumoto K
Osteoarthritis Cartilage; 2020 Nov; 28(11):1459-1470. PubMed ID: 32818603
[TBL] [Abstract][Full Text] [Related]
16. Genetic models of osteochondroma onset and neoplastic progression: evidence for mechanisms alternative to EXT genes inactivation.
Zuntini M; Pedrini E; Parra A; Sgariglia F; Gentile FV; Pandolfi M; Alberghini M; Sangiorgi L
Oncogene; 2010 Jul; 29(26):3827-34. PubMed ID: 20418910
[TBL] [Abstract][Full Text] [Related]
17. Multiple osteochondromas.
Bovée JV
Orphanet J Rare Dis; 2008 Feb; 3():3. PubMed ID: 18271966
[TBL] [Abstract][Full Text] [Related]
18. A splice-site mutation leads to haploinsufficiency of EXT2 mRNA for a dominant trait in a large family with multiple osteochondromas.
Yang L; Hui WS; Chan WC; Ng VC; Yam TH; Leung HC; Huang JD; Shum DK; Jie Q; Cheung KM; Cheah KS; Luo Z; Chan D
J Orthop Res; 2010 Nov; 28(11):1522-30. PubMed ID: 20872591
[TBL] [Abstract][Full Text] [Related]
19. Cell biology of osteochondromas: bone morphogenic protein signalling and heparan sulphates.
Cuellar A; Reddi AH
Int Orthop; 2013 Aug; 37(8):1591-6. PubMed ID: 23771188
[TBL] [Abstract][Full Text] [Related]
20. Unsuspected osteochondroma-like outgrowths in the cranial base of Hereditary Multiple Exostoses patients and modeling and treatment with a BMP antagonist in mice.
Sinha S; Mundy C; Bechtold T; Sgariglia F; Ibrahim MM; Billings PC; Carroll K; Koyama E; Jones KB; Pacifici M
PLoS Genet; 2017 Apr; 13(4):e1006742. PubMed ID: 28445472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
